2022 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
Public Comment Submitted to the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA)
Comment submitted prior to their meeting on November 17, 2022. Comment is in regard to discussion and voting on recommendation related to implementation of the HIV Organ Policy Equity (HOPE) Act of 2013, specifically pertaining to HIV-positive to HIV-positive organ transplantation and pertaining to the following draft recommendation under consideration regarding removal of the statutory “NIH Research Criteria and IRB” requirement.
TAGline November 2022
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies
On November 16, 2022, please join TAG, INPUD and AfroCAB for our webinar “Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies” at 8:00 a.m. EST / 02:00 p.m. CET / 05:30 IST.
Towards Pandemic Equity: Lessons from 30 Years of Syndemic Activism
By Mike Frick and Mark Harrington The articles in this 30th anniversary issue of TAGline grapple with “pandemic equity,” an increasingly common catchphrase in global health. COVID-19 has shown that “equity,” like its cousins “justice,” “fairness,” and “equality,” is one…
Treatment Action Group Statement: U.S. District Court Ruling Allowing Employers to Deny PrEP Coverage Is a Dangerous Attack on Public Health
Treatment Action Group (TAG) unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.
Pathways Forward to End HIV: How HIV Cure Research is Helping to Advance HIV Vaccine Research
On September 20, please join Treatment Action Group, Dr. Shelly Karuna, and Dr. Karine Dubé for a webinar on the next generation of bnAbs trial design and ethics related to ATIs in HIV vaccine and cure research.
Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci
Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.
Treatment Action Group Adds Three New Board Members
As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.